Vocabria (cabotegravir) is a small molecule pharmaceutical. Cabotegravir was first approved as Vocabria on 2020-12-17. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. Cabenuva's patent is valid until 2026-04-28 (FDA).
|Drug Class||Antivirals: integrase inhibitors|